Researchers from the University of Technology Sydney have introduced innovative smart nanoparticles that significantly enhance glioblastoma surgery. This dual-action technology not only illuminates hidden cancer cells during procedures but also targets residual tumors post-surgery. In mouse models, this approach achieved a remarkable 100% survival rate at 60 days, showing its potential as a breakthrough treatment for one of the most aggressive brain cancers.
Key Features of the Study
- The smart nanoparticles combine imaging and therapeutic functions, allowing surgeons to identify glioblastoma cells as small as 44 micrometers during surgery.
- After resection of the visible tumor, the nanoparticles assist in postoperative treatment by activating phototherapy and heat generation using near-infrared light.
- In the studies, this technique not only illuminated cancer cells but also significantly reduced recurrence. All treated mice survived beyond 60 days compared to an average survival of 42 days with traditional surgery alone.
- Glioblastoma is known to have a five-year survival rate of only about 7%, underscoring the urgent need for innovative treatment solutions such as this nanoparticle platform.
- The technology remains in early research stages and has not yet been tested in humans, but it holds promise for improving surgical outcomes and glioblastoma management.
